Last reviewed · How we verify
NCT05135520
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen
NA trial testing Transvaginal natural orifice specimen extraction (NOSE) in Urologic Neoplasms in 106 participants. Status unknown.
29 November 2022
Quick facts
| Lead sponsor | Seoul National University Bundang Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 29 November 2021 |
| Primary completion | 29 November 2022 |
| Estimated completion | 29 November 2023 |
Drugs / interventions tested
- Transvaginal natural orifice specimen extraction (NOSE)
- Transabdominal specimen extraction
Conditions studied
- Urologic Neoplasms — all drugs for Urologic Neoplasms →
Sponsor
Seoul National University Bundang Hospital
Who can join
20 and older, female only, with Urologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who are planning multiport laparoscopic surgery for resection of kidney.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05135520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transvaginal natural orifice specimen extraction (NOSE)
Trials testing the same drug.
- NCT05113134 — Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen · NA · completed
Other recruiting trials for Urologic Neoplasms
Currently open trials in the same condition.
- NCT07481851 — Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients · recruiting
- NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
- NCT06353906 — Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer · Phase 2 · recruiting
- NCT06237920 — Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab · Phase 2 · recruiting
- NCT05899361 — A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest · NA · recruiting
Other Seoul National University Bundang Hospital trials
Trials by the same sponsor.
- NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
- NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05135520 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
- Last refreshed: 26 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05135520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing